• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

European Commission Clears Label Extension for Roche’s Evrysdi


Treatment indicated for babies under two months old with spinal muscular atrophy.

 Licensed   FILE #:  220604681  Preview Crop  Find Similar DIMENSIONS 6701 x 4473px FILE TYPE JPEG CATEGORY Babies LICENSE TYPE Standard or Extended Cute newborn baby lies swaddled in a white blanket. Copy space and top view. Image Credit: Adobe Stock Images/irena_geo

Image Credit: Adobe Stock Images/irena_geo

In a company press release, Roche revealed that the European Commission (EC) has approved the extension of Evrysdi for infants with a clinical diagnosis of spinal muscular atrophy (SMA) from birth to below two months of age. The approval comes amid positive data from the ongoing rainbowfish trial in pre-symptomatic babies from birth to six weeks with type 1 SMA.

“With this label extension, we can treat babies soon after birth with Evrysdi, allowing them the greatest chance to achieve the milestones of sitting, standing, and walking, similar to healthy children,” said Levi Garraway, MD, PhD., chief medical officer, head of global product development, Roche, in the company release.

Reference: European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA). Roche. August 29, 2023. Accessed August 29, 2023. https://www.roche.com/media/releases/med-cor-2023-08-29

Related Videos
Related Content